Bellicum Pharmaceuticals, Inc (BLCM): Ken Moseley , Sr. VP and General Counsel of Bellicum Pharmaceuticals, Inc sold 11,800 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $20.07 per share for a total value of $237,202.08 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 20, 2016, Kevin M. Slawin (Chief Technology Officer) sold 4,584 shares at $20.00 per share price.On Sep 20, 2016, David M. Spencer (Chief Scientific Officer) sold 2,500 shares at $20.01 per share price.Also, On Sep 20, 2016, Ken Moseley (Sr. VP and General Counsel) sold 2,200 shares at $20.00 per share price.On Jun 6, 2016, Annemarie Moseley (COO/EVP Clinical Development) sold 25,000 shares at $13.00 per share price.
Shares of Bellicum Pharmaceuticals Inc (BLCM) ended Thursday, Sep 22, 2016 session in red amid volatile trading. The shares closed down -0.34 points or -1.73% at $19.31 with 2,04,410 shares getting traded. Post opening the session at $19.91, the shares hit an intraday low of $19.09 and an intraday high of $20 and the price vacillated in this range throughout the day. The company has a market cap of $522 M and the number of outstanding shares has been calculated to be 2,70,48,639 shares. The 52-week high of Bellicum Pharmaceuticals Inc is $23.84 and the 52-week low is $7.24.
Company has been under the radar of several Street Analysts.Bellicum Pharmaceuticals Inc is Upgraded by Citigroup to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Aug 9, 2016.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.